We provide you with 20 years of free, institutional-grade data for APLS stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of APLS. Explore the full financial landscape of APLS stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Chopas James George | Grant, award...etc | 38,244 | 2026-05-14 | ||
| MELTZER LESLIE | Grant, award...etc | 67,830 | 2026-05-14 | ||
| Sullivan Timothy Eugene | Grant, award...etc | 159,080 | 2026-05-14 | ||
| Deschatelets Pascal | Grant, award...etc | 90,040 | 2026-05-14 | ||
| Nicholson Nur | Grant, award...etc | 133,364 | 2026-05-14 | ||
| DeLong Mark Jeffrey | Grant, award...etc | 115,165 | 2026-05-14 | ||
| Boucher Kelley | Grant, award...etc | 45,219 | 2026-05-14 | ||
| Watson David O. | Grant, award...etc | 153,737 | 2026-05-14 | ||
| Francois Cedric | Grant, award...etc | 524,786 | 2026-05-14 | ||
| Baumal Caroline | Grant, award...etc | 67,646 | 2026-05-14 | ||
| Dolsten Mikael | Grant, award...etc | 14,312 | 2026-03-03 | ||
| DeLong Mark Jeffrey | Sale | -368 | $22.15 | $8,153 | 2026-02-13 |
| Francois Cedric | Derivatives Exercise | 8,840 | 2026-02-05 | ||
| Boucher Kelley | Grant, award...etc | 30,146 | 2026-01-30 | ||
| Chopas James George | Grant, award...etc | 16,150 | 2026-01-30 | ||
| DeLong Mark Jeffrey | Grant, award...etc | 36,606 | 2026-01-30 | ||
| Deschatelets Pascal | Grant, award...etc | 25,840 | 2026-01-30 | ||
| MELTZER LESLIE | Grant, award...etc | 45,220 | 2026-01-30 | ||
| Nicholson Nur | Grant, award...etc | 45,220 | 2026-01-30 | ||
| Sullivan Timothy Eugene | Grant, award...etc | 58,140 | 2026-01-30 | ||
| Watson David O. | Grant, award...etc | 55,986 | 2026-01-30 | ||
| Francois Cedric | Grant, award...etc | 195,952 | 2026-01-30 | ||
| Chopas James George | Sale | -2,064 | $21.77 | $44,924 | 2026-01-23 |
| DeLong Mark Jeffrey | Sale | -3,371 | $21.77 | $73,371 | 2026-01-23 |
| Watson David O. | Sale | -5,000 | $24.49 | $122,450 | 2025-12-18 |
| Watson David O. | Sale | -5,000 | $20.06 | $100,300 | 2025-11-18 |
| Sullivan Timothy Eugene | Sale | -10,000 | $28.03 | $280,300 | 2025-10-23 |
| Sullivan Timothy Eugene | Derivatives Exercise | 10,000 | 2025-10-23 | ||
| Watson David O. | Sale | -5,000 | $25.22 | $126,100 | 2025-10-17 |
| Dunlop A. Sinclair | Sale | -31,092 | $23.72 | $737,536 | 2025-10-15 |
| Dunlop A. Sinclair | Sale | -31,092 | $22.58 | $702,057 | 2025-10-02 |
| Dunlop A. Sinclair | Sale | -31,092 | $22.95 | $713,561 | 2025-09-19 |
| Watson David O. | Sale | -5,000 | $24.34 | $121,700 | 2025-09-18 |
| Chopas James George | Sale | -189 | $24.19 | $4,572 | 2025-09-17 |
| Watson David O. | Sale | -20,000 | $26.17 | $523,400 | 2025-09-12 |
| Sullivan Timothy Eugene | Sale | -10,000 | $27.83 | $278,300 | 2025-09-10 |
| Sullivan Timothy Eugene | Sale | -32,729 | $27.86 | $911,830 | 2025-09-10 |
| Sullivan Timothy Eugene | Derivatives Exercise | 15,000 | 2025-09-10 | ||
| Boucher Kelley | Grant, award...etc | 30,476 | 2025-09-03 | ||
| Chopas James George | Sale | -548 | $28.08 | $15,386 | 2025-09-03 |
| MELTZER LESLIE | Grant, award...etc | 61,804 | 2025-09-02 | ||
| Francois Cedric | Sale | -225,000 | $28.19 | $6,342,750 | 2025-08-29 |
| Watson David O. | Sale | -5,000 | $27.8 | $139,000 | 2025-08-19 |
| Watson David O. | Sale | -5,000 | $19.55 | $97,750 | 2025-07-18 |
| Francois Cedric | Sale | -19,725 | $20.21 | $398,735 | 2025-07-18 |
| Francois Cedric | Derivatives Exercise | 8,997 | 2025-07-18 | ||
| Francois Cedric | Sale | -139,365 | $20.19 | $2,813,278 | 2025-07-16 |
| Francois Cedric | Derivatives Exercise | 66,003 | 2025-07-16 | ||
| Chopas James George | Grant, award...etc | 6,250 | 2025-06-20 | ||
| Watson David O. | Sale | -5,000 | $18.77 | $93,850 | 2025-06-18 |
| Boucher Kelley | Grant, award...etc | 45,095 | 2025-06-11 | ||
| Boucher Kelley | Grant, award...etc | 22,087 | 2025-05-29 | ||
| Deschatelets Pascal | Derivatives Exercise | 12,780 | 2025-05-22 | ||
| WHEELER CRAIG A | Grant, award...etc | 16,483 | 2025-04-21 | ||
| Chopas James George | Sale | -183 | $24.82 | $4,543 | 2025-03-18 |
| Watson David O. | Sale | -5,569 | $25.1 | $139,789 | 2025-03-06 |
| DeLong Mark Jeffrey | Sale | -363 | $28.54 | $10,360 | 2025-02-12 |
| Lewis Karen | Sale | -364 | $29.52 | $10,747 | 2025-01-30 |
| Eisele Jeffrey | Sale | -278 | $29.52 | $8,208 | 2025-01-30 |
| Francois Cedric | Sale | -2,824 | $29.52 | $83,375 | 2025-01-30 |
| Deschatelets Pascal | Sale | -826 | $29.52 | $24,386 | 2025-01-30 |
| DeLong Mark Jeffrey | Sale | -365 | $29.52 | $10,776 | 2025-01-30 |
| Sullivan Timothy Eugene | Sale | -546 | $29.52 | $16,120 | 2025-01-30 |
| Nicholson Nur | Sale | -825 | $29.52 | $24,357 | 2025-01-30 |
| Watson David O. | Sale | -695 | $29.52 | $20,519 | 2025-01-30 |
| Townsend Adam J. | Sale | -695 | $29.52 | $20,519 | 2025-01-30 |
| Deschatelets Pascal | Sale | -3,948 | $30.43 | $120,120 | 2025-01-23 |
| DeLong Mark Jeffrey | Sale | -1,396 | $30.43 | $42,474 | 2025-01-23 |
| Chopas James George | Sale | -1,096 | $30.43 | $33,346 | 2025-01-23 |
| Watson David O. | Sale | -3,323 | $30.43 | $101,104 | 2025-01-23 |
| Sullivan Timothy Eugene | Sale | -3,088 | $30.43 | $93,954 | 2025-01-23 |
| Nicholson Nur | Sale | -3,948 | $30.43 | $120,120 | 2025-01-23 |
| Townsend Adam J. | Sale | -3,323 | $30.43 | $101,104 | 2025-01-23 |
The information provided in this report about APLS stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Apellis Pharmaceuticals, Inc(NASDAQ:APLS) 
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials fo...
Website: http://www.apellis.com
Founded: 2009
Full Time Employees: 350
Sector: Healthcare
Industry: Biotechnology